SWOG clinical trial number
CTSU/A082304/S2402

Perioperative Versus Adjuvant Systemic Therapy In Patients with Resectable Non-Small Cell Lung Cancer - PROSPECT LUNG, CTIU2317

Closed
Abbreviated Title
PROSPECT LUNG
Status Notes
Permanently closed on August 7, 2026.
Activated
12/11/2024
Closed
08/07/2026

Research committees

Lung Cancer

Treatment

Surgery

Publication Information Expand/Collapse

2025

Comparing impact of treatment before or after surgery in patients with stage II-IIIb resectable non-small cell lung cancer (NSCLC; Alliance A082304-SWOG S2402).

R Aljumaily;S Manrekar;Y Zhao;L Martin;D Kozono;S Hillman;A Chiang;R Osarogiagbon;T Stinchcombe;J Gray;D Morgensztern ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), poster; Abstract # TPS8113 Poster Bd # 234a

Other Clinical Trials

SWOG Clinical Trial Number
A082302

EVALUATING ADJUVANT ATEZOLIZUMAB OR ATEZOLIZUMAB AND HYALURONIDASE-TQJS TO PREVENT RECURRENCE IN STAGE I NON-SMALL CELL LUNG CANCER (NSCLC): A RANDOMIZED PHASE III TRIAL (AASI-NSCLC)
Research Committee(s)
Lung Cancer
Activated
03/02/2027
Open
SWOG Clinical Trial Number
S2409

PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Research Committee(s)
Lung Cancer
Activated
09/08/2025
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA5231

A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Research Committee(s)
Lung Cancer
Activated
06/13/2025
Open
Phase